Javier Meroño-Gallut

Javier Meroño-Gallut

Auto-generated profile, based on publicly available information

Javier Meroño-Gallut

InHeFis Research Group, Instituto Asturiano de Investigación Sanitaria (ISPA), 33011 Oviedo, Spain

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2022 in Journal of Blood Medicine
Verified
Journal Article
Open access
PDF file
Rubén Cuesta-BarriusoRubén Cuesta-Barriuso
Rubén Cuesta-Barriuso
EDElena Donoso-Úbeda
Elena Donoso-Úbeda
JMJavier Meroño-Gallut
Javier Meroño-Gallut
Roberto Ucero-LozanoRoberto Ucero-Lozano
Roberto Ucero-Lozano
RLRaúl Pérez Llanes
Raúl Pérez Llanes
Hemophilia is a congenital coagulopathy characterized by a deficiency of one of the clotting factors. It is characterized by the development of hematomas and hemarthrosis, either spontaneously or after minor trauma. The recurrence of hemarthroses leads to progressive and degenerative joint damage from childhood (hemophilic arthropathy). This arthropathy is characterized by disabling physical effects that limit the functionality and quality of life of these patients. Medical progress achieved over the last decade in the drug treatment of hemophilia has improved the medium and long-term prospects of patients with more effective and long-lasting drugs. The universal use of safer, more effective and prolonged prophylactic treatments may promote the prevention of bleeding, and also therefore, of the development of hemarthrosis and joint damage. A number of imaging instruments have been developed for the assessment of hemarthrosis and hemophilic arthropathy, using ultrasound, magnetic resonance imaging and simple radiology. Different physical examination scores and questionnaires allow the assessment of joint health, self-perceived activity and functionality of patients with hemophilia. The approach to these patients should be interdisciplinary. Assessment of the processes that affect pain in these patients and the development of pain education models should be implemented. Expert advice and information to patients with hemophilia should be based on individual functional prevention diagnoses, advice on available therapies and sports practice, as well as health recommendations.

8 March 2021 in Disability and Rehabilitation
Verified
Journal Article
Closed access
Rubén Cuesta-BarriusoRubén Cuesta-Barriuso
Rubén Cuesta-Barriuso
RLRaúl Pérez Llanes
Raúl Pérez Llanes
JLJosé-Antonio López-Pina
José-Antonio López-Pina
EDElena Donoso-Úbeda
Elena Donoso-Úbeda
JMJavier Meroño-Gallut
Javier Meroño-Gallut
To evaluate the effectiveness of manual therapy in reducing the frequency of clinical hemarthrosis, increasing range of motion and improving the perception of disability in the upper limbs in patie...

26 March 2024 in Physiotherapy Theory and Practice
Verified
Journal Article
Closed access
EDElena Donoso-Úbeda
Elena Donoso-Úbeda
Roberto Ucero-LozanoRoberto Ucero-Lozano
Roberto Ucero-Lozano
JMJavier Meroño-Gallut
Javier Meroño-Gallut
Rubén Cuesta-BarriusoRubén Cuesta-Barriuso
Rubén Cuesta-Barriuso
RLRaúl Pérez Llanes
Raúl Pérez Llanes
Hemophilia is a congenital coagulopathy characterized by a deficiency in blood levels of clotting factor VIII (hemophilia A) or IX (hemophilia B) proteins. This alteration prevents the normal blood...

31 July 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
AMAntonio Javier Meroño-Gallut
Antonio Javier Meroño-Gallut
Rubén Cuesta-BarriusoRubén Cuesta-Barriuso
Rubén Cuesta-Barriuso
RLRaúl Pérez Llanes
Raúl Pérez Llanes
EDElena Donoso-Úbeda
Elena Donoso-Úbeda
JLJosé-Antonio López-Pina
José-Antonio López-Pina
Background: Hemophilic ankle arthropathy is manifested by degenerative functional alterations and chronic pain. Myofascial release techniques are used to treat soft tissue adhesions, relieve pain, and reduce tissue sensitivity. Objective: This study aims to evaluate the safety and efficacy of a protocol using self-myofascial release with a foam roller to be applied in patients with hemophilic ankle arthropathy. Methods: Patients with ankle arthropathy (N=70) will be recruited, enrolled, and assigned to one of two groups—experimental or control—in a 1:1 allocation ratio. Patients will be recruited from 5 centers in different regions of Spain. Patient data will be collected at baseline, posttreatment, and follow-up. The primary outcome will be frequency of ankle joint bleeding (self-reported). The secondary outcomes will be ankle range of motion (measured with a digital goniometer); joint pain (measured with a visual analog scale and an algometer); joint status (measured using the Hemophilia Joint Health Score); muscle strength (measured with a dynamometer); functionality of lower limbs (measured using the 6-minute walking test); activity (self-reported); and muscle flexibility (measured using the fingertip-to-floor test). The treatment program includes 11 exercises that must be administered bilaterally. A mobile app will be developed where each patient will be able to observe the exercises to be carried out. Each session will last 15 minutes with 5 physiotherapy sessions per week for a period of 3 months. It is expected that patients with hemophilia who receive the foam roller intervention will show improvement in mobility, pain, and status of the ankle joint; muscle strength; and function in the lower extremities. Results: The study has been approved by the institutional review board of the University of Murcia. Patient recruitment will begin in September 2020, and the intervention period will last until June 2021. Data collection will take place between September 2020 and October 2021. Conclusions: This protocol describes a randomized clinical trial to examine the safety and efficacy of a self-myofascial release intervention using a foam roller in patients with hemophilic ankle arthropathy. Trial Registration: ClinicalTrials.gov NCT03914287; http://clinicaltrials.gov/ct2/show/NCT03914287. International Registered Report Identifier (IRRID): PRR1-10.2196/15612

9 June 2021 in Healthcare
Verified
Journal Article
Open access
PDF file
Rubén Cuesta-BarriusoRubén Cuesta-Barriuso
Rubén Cuesta-Barriuso
JMJavier Meroño-Gallut
Javier Meroño-Gallut
RLRaúl Pérez Llanes
Raúl Pérez Llanes
Roberto Ucero-LozanoRoberto Ucero-Lozano
Roberto Ucero-Lozano
(1) Background. The lockdown period due to the COVID−19 pandemic has drastically decreased levels of physical activity in the population. Hemophilia is characterized by hemarthrosis that leads to chronic, progressive and degenerative joint deterioration. (2) Methods. This observational study recruited 27 patients with hemophilia and arthropathy. Knee, ankle and elbow joints were assessed. The frequency of clinical hemarthrosis, pain intensity, pressure pain threshold, and joint ROM were evaluated. (3) Results. Following lockdown, a significant deterioration of joint condition, perceived joint pain and range of motion was noted in all joints. There were no changes in the frequency of knee hemarthrosis, while the frequency of ankle hemarthrosis significantly reduced. However, the frequency of elbow hemarthrosis increased. Depending on the degree of hemophilia severity, there were changes in pressure pain threshold in the elbow and in pain intensity and range of motion of the ankle joint. According to the type of treatment, i.e., prophylaxis vs. on-demand treatment, there were differences in the joint condition in elbows and the plantar flexion movement of the ankle. There were no differences in the knee joint based on the severity of the disease, the type of treatment or the development of inhibitors (4). Conclusions. Because of the COVID−19 lockdown, the musculoskeletal status of patients with hemophilia deteriorated. Joint condition, perceived pain, and range of motion were significantly affected. The frequency of clinical hemarthrosis did not increase during this period. A more active therapeutic model could prevent rapid deterioration in patients with hemophilic arthropathy during prolonged sedentary periods.

7 February 2025 in Haemophilia
Verified
Journal Article
Open access
CDCarlos Truque Díaz
Carlos Truque Díaz
JMJavier Meroño‐Gallut
Javier Meroño‐Gallut
Rubén Cuesta-BarriusoRubén Cuesta-Barriuso
Rubén Cuesta-Barriuso
RLRaúl Pérez Llanes
Raúl Pérez Llanes
Background: Haemophilic ankle arthropathy is characterized by chronic pain, loss of strength and proprioception, decreased range of motion (ROM) and impaired functionality. Objective: To evaluate the safety and efficacy of a manual therapy protocol based on joint and myofascial techniques in patients with haemophilic ankle arthropathy. Methods: A randomized, single‐blind pilot study. Twenty‐four patients with haemophilia were randomized to the experimental (manual therapy) and control (no intervention) groups. The intervention lasted for 3 weeks, with one 50‐min weekly session. Techniques used: active‐passive joint mobilization, articulatory technique, joint decompression and high‐speed and short‐stroke manipulation, and sustained myofascial induction techniques. The study variables were safety of the intervention (number of hemarthroses), joint pain intensity (visual analogue scale), pressure pain threshold (pressure algometer), range of ankle motion (Leg Motion) and joint condition (Haemophilia Joint Health Score). Results: None of the patients developed ankle hemarthrosis during the intervention. After the intervention there were intergroup differences in the variables pain intensity (MD = −0.45; p < 0.001), ROM (MD = 0.19; p = 0.003), joint condition (MD = 0.04; p = 0.03) and pressure pain threshold in the internal malleolus (MD = 1.36; p = 0.01). For the interaction time*group after the follow‐up period, there were statistically significant differences in pain intensity ( F = 6.94; p = 0.01) and dorsal flexion ( F = 3.36; p = 0.04) of the ankle. Conclusions: Manual therapy based on joint and myofascial techniques is safe in haemophilia patients. A protocol implementing joint and myofascial techniques having the dosage and safety parameters established in this study can improve the intensity of pain and dorsal flexion of the ankle in these patients. Trial Registration: ClinicalTrials.gov identifier: NCT05549843